Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topiramate for weight loss maintenance in obese patients
NCT00236600Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Aug 2000
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of topiramate in obesity (4 arms), sponsored by Johnson & Johnson. Primary endpoint: The percent change in body weight from the enrollment visit to week 60. Started Aug 2000; status: completed.
02
Drugs
topiramate
03
Conditions
obesity
Beyond the preview
Go deeper on NCT00236600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236600.